Virus-Like Particle & Nano-Particle Vaccines

20-22 June 2022, University of Latvia, Riga, Latvia

  • Increase font size
  • Default font size
  • Decrease font size

Day Two

Provisional Conference Programme | Tuesday 21st June 2022

SESSION 4:
PLANT-BASED VLPS

Moderator: To be confirmed

‘Plant VLPs in vaccine development’
Andris Zeltins
(University of Latvia, Riga, Latvia)

‘Plant based norovirus VLPs: From molecule design to phase I clinical trials’
Franziska Jarczowski
(Icon Genetics GmbH, Halle (Saale), Germany)

‘The suitability of plants for the production of Dengue Virus-like particles’
Daniel Ponnorf1, Yulia Meshcheriakova1, Hadrien Peyret1 and George P. Lomonossoff1
(1 Department for Biological Chemistry, John Innes Centre, Norwich, UK; 2 Plant Bioscience Ltd., Norwich Research Park, Norwich, UK)

‘The efficacy of a plant-produced virus-like particle vaccine against H6 avian influenza in specific-pathogen-free chickens’
T. Smith1,2, M.M. O’Kennedy1,2, D.B.R. Wandrag1, M. Adeyemi1 and C. Abolnik1
(1 Department of Production Animal Studies, Faculty of Veterinary Science, University of Pretoria, South Africa; 2 NextGen Health, Council for Scientific and Industrial Research, Pretoria, South Africa)

Coffee Break & Posters

SESSION 5:

Moderator to be confirmed

‘Affinity-selection on the MS2 VLP platform as a means for producing molecular mimics of vaccine antigens’
David Peabody
(University of New Mexico, Albuquerque, New Mexico, USA)

‘Monoclonal antibody – equivalent performance of IL17 – targeting VLP-vaccines’
Alexandra Moleda, Andris Zeltins, Martin Bachman and John Foerster
(University of Dundee, Dundee, Scotland, UK)

‘Immunological characterization of GMMA-based vaccines’
O. Rossi, M.G. Aruta, F. Mancini, A. Acquaviva, F. Citiulo, A. Podda, L.B. Martin, F. Micoli and F. Necchi
(GSK Vaccines Institute for Global Health S.r.l. (GVGH), Siena, Italy)

Lunch Break & Posters

SESSION 6:

Moderator: To be confirmed

‘Adjuvanted virosome VLP as flexible and potent universal vaccine platform for induction of systemic and mucosal immunity’
Mario Amacker, Toon Stegmann, Ronald Kempers and Sylvain Fleury
(Mymetics SA, Epalinges, Switzerland and Mymetics B.V., Leiden, The Netherlands)

‘1918 influenza Virus-Like Particle Vaccine structural analysis by cryo-electron microscopy with implications for viral surface glycoprotein vaccines’
Audray K. Harris, Dustin M. McCraw, John R. Gallagher, Udana Torian, Mallory L. Myers, Michael T. Conlon and Neetu M. Gulati
(Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA)

‘Live vaccine based on probiotic Enterococcus L3 strain containing conservative epitopes of influenza virus neuraminidase’
Yulia Desheva
(Institute of Experimental Medicine, St. Petersburg, Russian Federation)

Tea Break & Posters

SESSION 7:
VLP VACCINES

Moderator: To be confirmed

‘Exploration and development of a novel personalized breast-cancer vaccine based on virus-like particles by incorporating tumor-specific T-cell epitopes’
Mona O. Mohsen1, Monique Vogel1, Said Dermime2, Varghese Inchakalody2, Daniel Speiser3, Alexander Knuth2, Michal Bassani3 and Martin F. Bachmann1
(1 Department of BioMedical Research, Immunology RIA, University of Bern, Bern, Switzerland; 2 Interim Translational Research Institute “iTRI”, National Center for Cancer Care & Research (NCCCR), Doha, State of Qatar; 3 Department of Oncology, University of Lausanne, Lausanne, Switzerland)

‘Bacteriophage virus-like particle vaccines for opioids’
Kathryn M. Frietze
(University of New Mexico School of Medicine, Albuquerque, New Mexico, USA)

‘Novel HBV S/preS1 chimeric antigen particles produced in mammalian cells and plants induce stronger immune response than the standard vaccine, S’
Mihaela-Olivia Dobrica1, Catalin Lazar1, Lisa Paruch2, Andre van Eerde2, Hege Steen2, Sissel Haugslien2, Catalin Tucureanu3, Iuliana Caras3, Sonya Ciulean3, Adrian Onu3, Crina Stavaru3, Alexandru Branzan4, Jihong Liu Clarke2 and Norica Nichita1
(1 Institute of Biochemistry of the Romanian Academy, Bucharest, Romania; 2 NIBIO - Norwegian Institute for Bioeconomy Research, Ås, Norway; 3 “Cantacuzino” National Research Institute, Bucharest, Romania; 4 Institute of Biology of the Romanian Academy, Bucharest, Romania)

 

VLPNPV 2022 Delegates

Login details will be supplied after you have registered for the event.


VLPNPV 2022 Sponsors

  • Croda
  • NanoFCM
  • John Innes Centre
  • Anovasia
  • APACI
  • Mymetics
  • Medigen

VLPNPV 2022 Mailing List

Name
E-mail Address
What is 3+2-1?